Table 5: Log-rank and Cox regression tests for BPFS and clinical PFS in the 294 cases analyzed.

Parameters Biochemical progressionClinical progression
Events%BPFSP-univariateHR95% CIP-multivariateEvents% Clinical PFSP-univariateHR95% CIP-multivariate

PSA
 ≤10 ng/mL1863753.610.0012077.7
 10–20 ng/mL662650.4<0.0012.91.6–5.3<0.0011852.30.015NS
 >20 ng/mL422028.21.60.8–30.1181251.9
Gleason-sp
 2–61182167.71<0.0011178.410.001
 71393946.3<0.0014.42.2–8.5<0.0012659<0.0014.82–11.1<0.001
 >7372303.21.8–5.7<0.00113482.51.3–50.008
cT
 ≤cT2b2747251.40.001NS4565.70.410NS
 ≥cT3a191126.4565.4
pT
 ≤pT21612468.3<0.001NS1477.80.001NS
 ≥pT31335935.43656.7
pN
 pN06612550<0.00110.0334067.60.004NS
 pN ≥ 19102.31.1–5.1533.8
Perineural inv.
 Negative1262456.9<0.00110.0011382.90.00110.013
 Positive1445844.72.41.4–43650.82.31.2–4.5
TMPRSS2-ERG
 Negative1323158.71874.3
 Translocation1183939.30.2292460.10.380
 Deletion351039.4672.4
Fusion gene status
 Negative12735510.82422680.855
 Positive1664748.22667.7

SP: specimen, BPFS: biochemical progression free survival, PFS: progression free survival, and NS: not significant.